• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Henry Schein Inc.

    3/19/26 12:30:49 PM ET
    $HSIC
    Medical Specialities
    Health Care
    Get the next $HSIC alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0002057014
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    HENRY SCHEIN INC
    SEC File Number
    000-27078
    Address of Issuer
    135 DURYEA RD
    MELVILLE
    NEW YORK
    11747
    Phone
    6318435500
    Name of Person for Whose Account the Securities are To Be Sold
    Popeck Thomas C
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    135598630.4511470412103/19/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common03/03/2025Restricted Stock VestingIssuerCheckbox not checked14403/03/2025Compensation
    Common03/01/2026Restricted Stock VestingIssuerCheckbox not checked19103/01/2026Compensation
    Common03/16/2026Restricted Stock VestingIssuerCheckbox not checked102003/16/2026Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    03/19/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Jared Cook, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Thomas Popeck

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $HSIC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSIC

    DatePrice TargetRatingAnalyst
    4/16/2026Neutral
    BTIG Research
    4/15/2026$100.00Buy
    Citigroup
    2/23/2026$100.00Neutral → Outperform
    Robert W. Baird
    12/9/2025$86.00Overweight
    Barclays
    8/26/2025$83.00In-line → Outperform
    Evercore ISI
    7/25/2025$75.00Buy → Hold
    Stifel
    7/14/2025$72.00Outperform → Neutral
    Robert W. Baird
    2/14/2025$80.00Equal Weight
    Wells Fargo
    More analyst ratings

    $HSIC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Henry Schein Announces the Election of William K. "Dan" Daniel as Independent Chairman of the Board

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced that its Board of Directors has elected William K. "Dan" Daniel as Independent Chairman of the Board, effective May 21, 2026. Mr. Daniel succeeds Stanley M. Bergman, who retired from the Board following 44 years as a Director of Henry Schein and was named Chairman Emeritus in recognition of his extraordinary contributions to the Company. Mr. Daniel joined the Henry Schein Board of Directors in May 2025. He possesses decades of board and global executive leadership experience in healthcare and industrial sectors, including serving for 14

    5/22/26 8:00:00 AM ET
    $DHR
    $HSIC
    $NVST
    Industrial Machinery/Components
    Industrials
    Medical Specialities
    Health Care

    Henry Schein One Releases 2026 Catalyst Index, Revealing Clinical Performance as the Primary Driver of Growth

    Top performers achieve 75% case acceptance vs. 45% industry average, signaling that clinical consistency, not scale alone, drives predictable growth and enterprise value Henry Schein One, the global leader in dental technology, today announced the release of its 2026 Catalyst Index, the fifth edition of its annual benchmarking report analyzing performance across tens of thousands of DSOs, multi-location organizations, and private practices. This year's data points to a clear and urgent shift for the industry: in a slower economy, growth is no longer determined by scale or efficiency alone; it is driven by clinical execution. Across both DSOs and independent practices, the highest-perf

    5/14/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Reports First Quarter 2026 Financial Results

    Q1 2026 GAAP diluted EPS of $0.92 compared to $0.88 GAAP diluted EPS in Q1 2025 Q1 2026 non-GAAP diluted EPS of $1.32 compared to $1.15 non-GAAP diluted EPS in Q1 2025 Reaffirming guidance for 2026 sales, non-GAAP diluted EPS, and Adjusted EBITDA Confirming that value creation initiatives are expected to deliver over $200 million of operating income improvement over the next few years, with $125 million run-rate by year-end 2026 Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the first quarter ended March 28, 2026. "I am pleased with our strong first

    5/5/26 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Henry Schein

    BTIG Research initiated coverage of Henry Schein with a rating of Neutral

    4/16/26 8:03:48 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Citigroup initiated coverage on Henry Schein with a new price target

    Citigroup initiated coverage of Henry Schein with a rating of Buy and set a new price target of $100.00

    4/15/26 8:08:55 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Henry Schein from Neutral to Outperform and set a new price target of $100.00

    2/23/26 8:29:17 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    SEC Filings

    View All

    SEC Form SD filed by Henry Schein Inc.

    SD - HENRY SCHEIN INC (0001000228) (Filer)

    5/29/26 3:04:28 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    5/22/26 8:00:11 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form DEFA14A filed by Henry Schein Inc.

    DEFA14A - HENRY SCHEIN INC (0001000228) (Filer)

    5/12/26 9:00:08 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Murphy Kelly Ann claimed ownership of 34,812 shares (SEC Form 3)

    3 - HENRY SCHEIN INC (0001000228) (Issuer)

    5/28/26 5:01:47 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Amendment: Former Director Bergman Stanley M gifted 50 shares, decreasing direct ownership by 0.02% to 253,279 units (SEC Form 4)

    4/A - HENRY SCHEIN INC (0001000228) (Issuer)

    5/26/26 5:16:26 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Director Bergman Stanley M gifted 50 shares, decreasing direct ownership by 0.02% to 253,279 units (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    5/22/26 7:03:42 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Daniel William K bought $691,900 worth of shares (10,000 units at $69.19) (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    5/12/26 4:15:46 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Director Daniel William K bought $670,800 worth of shares (10,000 units at $67.08) (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/11/25 4:26:33 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Leadership Updates

    Live Leadership Updates

    View All

    Henry Schein Enters Exclusive Distribution Agreement for CytoChip's CLIA-Waived Hematology Analyzer

    Partnership Expands Access to FDA-Cleared CitoCBC® System Across the U.S. Henry Schein, Inc. (NASDAQ:HSIC) has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC® system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115495488/en/CLIA Waived CitoCBC System Des

    1/15/26 10:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Names Frederick M. Lowery as Chief Executive Officer

    Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire

    1/12/26 7:00:00 AM ET
    $HSIC
    $TMO
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Stanley M. Bergman to Retire as Henry Schein's Chief Executive Officer at the End of 2025

    Mr. Bergman to Continue to Serve as Chairman of the Board Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that Stanley M. Bergman will retire as Chief Executive Officer (CEO) at the end of the year after 45 years at the Company, including more than 35 years as CEO. Mr. Bergman will continue to lead Henry Schein in his current role until his retirement and will remain as Chairman thereafter. The Board is commencing a formal search process in conjunction with a nationally recognized executive search firm and will consider internal and external candidates. "With the progress made advan

    7/15/25 7:05:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Financials

    Live finance-specific insights

    View All

    Henry Schein Reports First Quarter 2026 Financial Results

    Q1 2026 GAAP diluted EPS of $0.92 compared to $0.88 GAAP diluted EPS in Q1 2025 Q1 2026 non-GAAP diluted EPS of $1.32 compared to $1.15 non-GAAP diluted EPS in Q1 2025 Reaffirming guidance for 2026 sales, non-GAAP diluted EPS, and Adjusted EBITDA Confirming that value creation initiatives are expected to deliver over $200 million of operating income improvement over the next few years, with $125 million run-rate by year-end 2026 Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the first quarter ended March 28, 2026. "I am pleased with our strong first

    5/5/26 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein to Webcast First Quarter 2026 Conference Call on Tuesday, May 5, 2026, at 8:00 A.M. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that it will release its first quarter 2026 financial results before the stock market opens on Tuesday, May 5, 2026, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Frederick M. Lowery, Chief Executive Officer and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on the Henry Schein website following the prese

    4/21/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Reports Fourth Quarter and Full Year 2025 Financial Results and Introduces 2026 Financial Guidance

    Q4 2025 GAAP diluted EPS of $0.85, compared to $0.74 GAAP diluted EPS in Q4 2024 Q4 2025 non-GAAP diluted EPS of $1.34, compared to $1.19 non-GAAP diluted EPS in Q4 2024 2026 non-GAAP diluted EPS expected to be in the range of $5.23 to $5.37, with total sales growth expected to be 3-5% Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the fourth quarter ended December 27, 2025. "Our fourth-quarter sales reflect continuing momentum resulting in the highest sales growth in 15 quarters. We are pleased with the sales results across all our businesses, particul

    2/24/26 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Henry Schein Inc.

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    11/13/24 3:30:01 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Henry Schein Inc.

    SC 13G - HENRY SCHEIN INC (0001000228) (Subject)

    11/12/24 9:32:27 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Henry Schein Inc. (Amendment)

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    2/14/24 11:18:57 AM ET
    $HSIC
    Medical Specialities
    Health Care